Status:
COMPLETED
First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors
Lead Sponsor:
Pfizer
Conditions:
Advanced Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of the study was to characterize the safety of investigational agent AG-013736, in patients with solid tumors in this First In Human trial.
Eligibility Criteria
Inclusion
- Patients with cytologically or histologically confirmed solid tumor(s) and with at least one measurable disease site
- Patients with adequate bone marrow, liver and kidney function
- Patients with life expectancy of at least 12 weeks
Exclusion
- Patients who have received chemotherapy, immunotherapy, radiotherapy or any investigational agent within 4 weeks of study entry
- Patients with have had a major surgical procedure within 4 weeks of study entry
Key Trial Info
Start Date :
November 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2004
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT01469052
Start Date
November 1 2002
End Date
August 1 2004
Last Update
March 26 2012
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
San Francisco, California, United States, 94115
2
Pfizer Investigational Site
Houston, Texas, United States, 77030
3
Pfizer Investigational Site
Madison, Wisconsin, United States, 53792